Need professional-grade analysis? Visit stockanalysis.com
$272.70M
N/A
N/A
N/A
Polaryx Therapeutics, Inc. Common Stock (PLYX) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $6.12, down 4.23% from the previous close.
Over the past year, PLYX has traded between a low of $2.41 and a high of $22.50. The stock has lost 72.1% over this period. It is currently 72.8% below its 52-week high.
Polaryx Therapeutics, Inc. Common Stock has a market capitalization of $272.70M.
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Side-by-side comparison against top Healthcare peers.